Immune adverse events (irAEs) with adjuvant ipilimumab in melanoma, use of immunosuppressants and association with outcome: ECOG-ACRIN E1609 study analysis

BACKGROUND: The impact of immune-related adverse events (irAEs) occurring from adjuvant use of immunotherapy and of their management on relapse-free survival (RFS) and overall survival (OS) outcomes is currently not well understood. PATIENTS AND METHODS: E1609 enrolled 1673 patients with resected hi...

Descripción completa

Detalles Bibliográficos
Autores principales: Tarhini, Ahmad A, Kang, Ni, Lee, Sandra J, Hodi, F Stephen, Cohen, Gary I, Hamid, Omid, Hutchins, Laura F, Sosman, Jeffrey A, Kluger, Harriet M, Eroglu, Zeynep, Koon, Henry B, Lawrence, Donald P, Kendra, Kari L, Minor, David R, Lee, Carrie B, Albertini, Mark R, Flaherty, Lawrence E, Petrella, Teresa M, Streicher, Howard, Sondak, Vernon K, Kirkwood, John M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2021
Materias:
Clinical/Translational Cancer Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8108687/
https://www.ncbi.nlm.nih.gov/pubmed/33963015
http://dx.doi.org/10.1136/jitc-2021-002535

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8108687/
https://www.ncbi.nlm.nih.gov/pubmed/33963015
http://dx.doi.org/10.1136/jitc-2021-002535

Ejemplares similares